share_log

Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $55

Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $55

Chardan Capital维持对新兴生物解决方案的买入,将目标股价下调至55美元
Benzinga Real-time News ·  2022/11/09 07:38

Chardan Capital analyst Keay Nakae maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $65 to $55.

Chardan Capital分析师Keay Nakae维持Emergent BioSolutions(纽约证券交易所代码:EBS)的买入,并将目标股价从65美元下调至55美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发